Dianthus Therapeutics
DNTH · Nasdaq · United States
Share price · DNTH
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when DNTH's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 30 Jul 2026+8.2%
Nothing announced by DNTH that day or the session before.
- 17 Jul 2026+10.7%
Nothing announced by DNTH that day or the session before.
- 1 Jul 2026-7.5%
Nothing announced by DNTH that day or the session before.
- 12 Jun 2026+7.4%
Nothing announced by DNTH that day or the session before.
- 10 Jun 2026-9.6%
Nothing announced by DNTH that day or the session before.
- 10 Mar 2026+9.7%
Nothing announced by DNTH that day or the session before.
- 9 Mar 2026+21.5%
Nothing announced by DNTH that day or the session before.
- 4 Mar 2026+12.0%
Nothing announced by DNTH that day or the session before.
- 22 Jan 2026+9.8%
Nothing announced by DNTH that day or the session before.
- 13 Jan 2026+14.7%
Nothing announced by DNTH that day or the session before.
Share of unusual movement by asset
For each asset, the share of DNTH's own-move activity since 17 Oct 2025 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
| Asset | Event days | Share of unusual movement |
|---|---|---|
LBL-047events and moves
| 1 | shown from 8 days |
| Assets with fewer than 8 event days, together | — | 0% |
| Other company news (earnings, financing, releases naming no asset) | — | 1% |
| Sessions with no dated event | — | 99% |
Assets
(1 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 1 | BDCA2 (CLEC4C) / TACIProtein / enzyme therapeutic | Systemic Lupus Erythematosus |
Upcoming events
No upcoming trial completions or earnings dates on record for this company's assets.
Financial reports
Quarterly & interim (15)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | — | $46M | $56M+ $782M short-term inv. | $47M-$50M operating cash flow | report ↗ |
View 14 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | — | $49M | $111M+ $776M short-term inv. | $50M-$49M operating cash flow | report ↗ |
| 2026-Q1 | — | $35M | $628M+ $484M short-term inv. | $41M-$29M operating cash flow | report ↗ |
| 2025-Q3 | $0.4M | $32M | $56M+ $347M short-term inv. | $37M-$31M operating cash flow | report ↗ |
| 2025-Q2 | $0.2M | $26M | $13M+ $244M short-term inv. | $32M-$24M operating cash flow | report ↗ |
| 2025-Q1 | $1.2M | $27M | $10M+ $253M short-term inv. | $30M-$28M operating cash flow | report ↗ |
| 2024-Q3 | $2.2M | $26M | $34M+ $247M short-term inv. | $25M-$21M operating cash flow | report ↗ |
| 2024-Q2 | $1.9M | $18M | $314M+ $47M short-term inv. | $18M-$15M operating cash flow | report ↗ |
| 2024-Q1 | $0.9M | $13M | $330M+ $47M short-term inv. | $14M-$15M operating cash flow | report ↗ |
| 2023-Q3 | $0.9M | $8.0M | $157M+ $33M short-term inv. | $15M$17M operating cash flow | report ↗ |
| 2023-Q2 | — | $0.1M | $63M+ $15M short-term inv. | $3.3M-$6.5M operating cash flow | report ↗ |
| 2023-Q1 | — | $8.0M | $50M+ $30M short-term inv. | $29M-$36M operating cash flow | report ↗ |
| 2022-Q3 | $1.2M | $11M | $61M+ $69M short-term inv. | $16M-$14M operating cash flow | report ↗ |
| 2022-Q2 | — | $12M | $57M+ $85M short-term inv. | $17M-$17M operating cash flow | report ↗ |
| 2022-Q1 | — | $17M | $74M+ $85M short-term inv. | $23M-$20M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $2.0M | $146M | $51M+ $353M short-term inv. | $41M-$129M operating cash flow | report ↗ |
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | $6.2M | $83M | $23M+ $252M short-term inv. | $21M-$78M operating cash flow | report ↗ |
| 2023-FY | $2.8M | $33M | $132M+ $41M short-term inv. | $11M-$37M operating cash flow | report ↗ |
| 2022-FY | $6.4M | $55M | $59M+ $60M short-term inv. | $19M-$67M operating cash flow | report ↗ |
| 2021-FY | $1.5M | $47M | $133M+ $0 short-term inv. | $18M-$60M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 0 purchases ($0), 71 sales ($75.1M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-11-12 | Savitz Ryan · EVP, CFO & CBO | Option exercise | 1,339 | $21.77 | $29K | Form 4 |
| 2026-11-12 | Savitz Ryan · EVP, CFO & CBO | Option exercise | 16,385 | $22.07 | $362K | Form 4 |
| 2026-11-12 | Savitz Ryan · EVP, CFO & CBO | Open-market sale | 17,724 | $90.56 | $1.6M | Form 4 |
| 2026-11-12 | Savitz Ryan · EVP, CFO & CBO | Option exercise (derivative) | 1,339 | — | — | Form 4 |
| 2026-11-12 | Savitz Ryan · EVP, CFO & CBO | Option exercise (derivative) | 16,385 | — | — | Form 4 |
| 2026-11-11 | Savitz Ryan · EVP, CFO & CBO | Option exercise | 1,744 | $21.77 | $38K | Form 4 |
| 2026-11-11 | Savitz Ryan · EVP, CFO & CBO | Option exercise | 1,300 | $22.07 | $29K | Form 4 |
| 2026-11-11 | Savitz Ryan · EVP, CFO & CBO | Open-market sale | 3,044 | $90.03 | $274K | Form 4 |